Skip to content
BillHelp
Menu
YOUR BILLHELP GUIDE

Allergy Testing or Shots Not Covered

What can I do if allergy testing or allergy shots were denied or billed to me?

A denial of allergy testing or allergy shots usually turns on whether the plan says the service was medically necessary, whether it required approval first, or whether the number of tests was more than the plan allows. Original Medicare uses national coverage rules for some food and sublingual methods, and local coverage determinations for other testing and for allergy shots. Those local rules are not the same in every state. Ask for the itemized bill and the denial reason, then appeal the decision you actually received. This page does not promise coverage.

Get help with my bill →
General U.S. guidance. Your plan documents and denial notice explain the process that applies to your case. Medicare, Medicaid, and other programs may use different rules. This is not medical or legal advice, and no result is guaranteed.

Start with the reason on the denial

Read the denial before you argue about the science. "Not medically necessary," "too many tests," "no prior authorization," and "not a covered benefit" are different requests. A medical-necessity denial is explained in a medical-necessity denial. A missing approval is in a prior-authorization denial. A benefit exclusion is in a service the plan says is not covered. A lab line for a blood test has its own checklist in a lab test the plan did not cover.

HealthCare.gov's glossary says preauthorization, also called prior authorization, is a decision by your insurer or plan that a health care service, treatment plan, prescription drug, or durable medical equipment is medically necessary. It says a plan may require preauthorization for certain services before you receive them, except in an emergency, and that preauthorization is not a promise the plan will cover the cost. Not every plan requires it for allergy testing or for shots. Ask this plan whether it required approval, whether a request was submitted, and what was approved. If shots continue after an approval period, ask whether a new authorization is required. Do not assume a testing approval covers the shots, or the reverse.

For a private plan, the plan document and the denial control. This page does not state a national private-plan rule for how many allergy tests are covered. Use the Medicare sections below only if the claim was Original Medicare, or the plan says it follows a Medicare local coverage determination. A Medicare Advantage plan can use its own coverage rules. Ask the plan which policy it applied.

References: HealthCare.gov: Preauthorization

What does a Medicare allergy-testing policy limit?

The Medicare Coverage Database page for local coverage determination L40328 is titled Allergy Diagnostic Testing. It is Palmetto GBA's policy for Alabama, Georgia, Tennessee, South Carolina, Virginia, West Virginia, and North Carolina. The page says it is effective for services performed on or after September 27, 2026. Another Medicare Administrative Contractor can use a different local policy, or none with this number. Ask which contractor processed the claim, and open that contractor's policy. Do not treat L40328 as a national rule.

L40328 says it addresses testing for immediate IgE-mediated reactions and delayed cell-mediated reactions. It says allergy testing is covered when it has proven efficacy, and that the record should show a history and physical examination with testing based on reasonable exposure to the suspected allergens. It says skin testing is the first-line method for type I IgE-mediated hypersensitivity related to allergic conjunctivitis, rhinitis, asthma, dermatitis, food, drug, venom, and some occupational allergies. It says serum specific IgE testing is covered in listed situations, including contraindications to skin testing from widespread skin disease, medicines that affect skin testing and cannot safely be stopped, patients who cannot cooperate, patients for whom the anaphylaxis risk of skin testing outweighs the benefit, uncontrolled asthma, and inconclusive skin tests when cross-reactivity or ongoing suspicion remains.

On the number of tests, L40328 says an inhalant allergy evaluation may require up to 70 percutaneous tests and up to 40 intracutaneous tests if the percutaneous tests are negative, and that more than 70 percutaneous tests and 40 intracutaneous tests would not be reasonable and necessary. It says patch tests may require up to 80 to 90 tests, and that more than 90 would not be reasonable and necessary. It says routine repeat testing is not reasonable and necessary unless the record supports the need, such as a change in exposure, new signs or symptoms, or lack of effect of current immunotherapy. It says routine in vitro testing in addition to skin testing for the same antigen is not reasonable and necessary, except for suspected latex, Hymenoptera, or nut or peanut sensitivity, where both may be performed when indicated. It says qualitative multiallergen screens that report only a single positive or negative, without identifying individual allergens, are not reasonable and necessary. It says a multiplex microarray that assesses several allergen categories at once is screening, and is not reasonable and necessary when the history, signs, symptoms, exposures, or differential diagnosis do not clearly support it.

The same LCD says an oral challenge is allowed once per patient encounter, regardless of how many items are tested. It says home testing, not done in the office under medical supervision, will not be covered. It cites national coverage determination 110.11 for the exclusion of sublingual, intracutaneous, and subcutaneous provocative and neutralization testing and neutralization therapy for food allergies, and national coverage determination 110.12 for challenge ingestion food testing used to diagnose rheumatoid arthritis, depression, or a respiratory disorder. This page relies on NCD 110.11 as opened on the Medicare Coverage Database, below, and does not restate NCD 110.12 beyond what L40328 says about it.

The Medicare Coverage Database page for an LCD also says procedure and diagnosis codes have moved from LCDs to billing and coding articles. L40328, as opened here, states test counts and methods. It does not list billing-code numbers in the coverage text this page is using. Do not add code numbers from memory. Ask the office for the itemized bill, ask which codes were sent, and look those codes up in the billing and coding article for your contractor and your state.

References: CMS Medicare Coverage Database LCD L40328: Allergy Diagnostic Testing, Palmetto GBA · CMS NCD 110.11: Food allergy testing and treatment

What does Medicare say about allergy shots?

National coverage determination 110.9, Antigens Prepared for Sublingual Administration, says that for antigens provided on or after November 17, 1996, Medicare does not cover antigens if they are to be administered sublingually, by placing drops under the tongue. It says this kind of allergy therapy has not been proven safe and effective. It says antigens are covered only if they are administered by injection.

National coverage determination 110.11 says that effective October 31, 1988, sublingual intracutaneous and subcutaneous provocative and neutralization testing and neutralization therapy for food allergies are excluded from Medicare coverage because available evidence does not show that these tests and therapies are effective. If the bill is for drops, or for provocative neutralization treatment for a food allergy, ask whether the denial is one of these national exclusions. A national exclusion is not fixed by adding more clinical notes, unless the service was something else and was coded wrong.

Local coverage determination L36240, Allergen Immunotherapy, is Novitas Solutions' policy. The Medicare Coverage Database page lists Colorado, New Mexico, Oklahoma, Texas, Arkansas, Louisiana, Mississippi, Delaware, the District of Columbia, Maryland, New Jersey, and Pennsylvania. The revision on that page is for services performed on or after March 31, 2024. It is not a national policy. Another contractor may use a different LCD.

L36240 says immunotherapy is the repeated administration of specific allergens to people with IgE-mediated conditions. It says both of these must be met: the allergens are clinically relevant, and a trial of avoidance failed or exposure cannot be avoided. It lists conditions for which immunotherapy will be considered medically reasonable and necessary: allergic rhinitis, allergic conjunctivitis, allergic asthma, dust mite atopic dermatitis, and stinging insect hypersensitivity. It says the presence of IgE antibodies alone does not show a need for immunotherapy. The antibodies have to correlate with the history.

L36240 says immunotherapy is not considered medically reasonable and necessary for food hypersensitivity, cockroach hypersensitivity, urticaria or angioedema, provocation-neutralization therapy, low-dose subcutaneous therapy based on the Rinkel method, or formulations such as allergoids or adjuvants. It lists routes it does not treat as reasonable and necessary, including oral or sublingual food immunotherapy, epicutaneous, intralymphatic, intranasal, and sublingual immunotherapy. It also says there are currently no FDA-approved formulations for a non-injection immunotherapy extract, in the passage explaining why those methods are not supported. That sentence is the LCD's statement as revised for services on or after March 31, 2024. If a newer product is at issue, ask the contractor which policy it is applying now. The LCD says the duration of immunotherapy must be individualized. It says that for many patients the recommended duration is 3 to 5 years. It does not make 3 to 5 years a guarantee of payment.

Both LCDs cite the statute that Medicare does not pay for items or services that are not reasonable and necessary for the diagnosis or treatment of illness or injury. A denial that uses those words is asking for the record that matches the policy: the history, the test results, and why shots were started. Your clinician can supply that. You can file the appeal. See how to appeal an Original Medicare denial.

References: CMS NCD 110.9: Antigens prepared for sublingual administration · CMS NCD 110.11: Food allergy testing and treatment · CMS Medicare Coverage Database LCD L36240: Allergen Immunotherapy, Novitas Solutions

How do I read the bill without guessing the codes?

Ask for an itemized bill that lists each test or injection, the date, and the code the office sent. Count the tests if the bill lists them one by one. If you are in a Palmetto state and the service date is on or after September 27, 2026, compare an inhalant panel with L40328's 70 and 40 figures, and a patch panel with its statement that more than 90 tests would not be reasonable and necessary. If you are outside those states, do not use those figures. Ask the contractor for the limit in its own article.

Separate the testing bill from the shot bill. Testing on one date and injections on later dates are not duplicates only because both say "allergy." Shots given on a schedule can be many claims. Ask which dates were billed and which were visits you attended. A fee for a visit you missed is a different charge from a denied test. Ask the office to label it that way if that is what it is.

If the plan paid, compare the bill with the patient balance on the explanation of benefits for that claim. If the plan denied the line, the appeal is about the denial, not about subtracting the explanation of benefits from the charges.

References: CMS Medicare Coverage Database LCD L40328: Allergy Diagnostic Testing, Palmetto GBA

When do I appeal?

Appeal when the plan or Medicare denied a service you believe meets the policy, or when the number of tests on the claim is not the number that were done. Use the denial's instructions and deadline. For a commercial plan, HealthCare.gov describes an internal appeal and, for many plans, an external review. See how to appeal a health insurance denial. Ask the clinician for the history, the results, and a sentence on why the tests or the shots were ordered. Send that with the appeal if the notice asks for clinical information.

If the denial is a national noncoverage, such as sublingual antigens under NCD 110.9, say so plainly and ask whether a different service was billed by mistake. An appeal that only repeats that you need the treatment does not change a national exclusion. If the denial is "too many units," ask the office whether it can correct the claim to the number supported by the chart, which may be faster than an appeal of a count the chart does not support.

References: HealthCare.gov: Internal appeals · HealthCare.gov: External review · CMS NCD 110.9: Antigens prepared for sublingual administration

What this page cannot promise

This is general information, not medical advice. L40328 applies to Palmetto GBA's states for services on or after September 27, 2026. L36240 applies to Novitas Solutions' states for services on or after March 31, 2024. Other contractors can differ. NCD 110.9 and NCD 110.11 are national exclusions for the methods they name. A private plan may cover more, or less, than Medicare. Nothing on this page promises that a plan will pay for testing or for shots.

Sources and further help

These sources provide general guidance. For a deadline or requirement that applies to you, follow your plan’s notice or the appropriate program’s current instructions.

Insurer websites may ask you to select your state or sign in. If a page will not open, use the member services number on your insurance card and ask for the current appeal instructions for your plan.

Report a broken link or suggest a correction.

← Explore all 141 guides